Summary & Overview
Revision of Hip or Knee Replacement without CC/MCC: Inpatient Reimbursement Overview
DRG 468 encompasses inpatient revision of hip or knee replacement without Major Complication or Comorbidity and without Complication or Comorbidity; it defines the clinical scope of moderate-complexity joint revision admissions. Proper assignment matters for inpatient reimbursement because it places cases into a specific Medicare Severity Diagnosis-Related Group payment tier that reflects typical resource needs.
DRG 468 Overview
DRG 468 covers inpatient admissions for revision of hip or knee replacement procedures without a Major Complication or Comorbidity and without a Complication or Comorbidity. These cases typically involve surgical revision for prosthesis-related issues such as loosening, wear, or malalignment but without additional coded complications that would increase resource use. This Diagnosis-Related Group is important for Centers for Medicare & Medicaid Services payment because it groups patients with moderate resource utilization into a payment weight distinct from more complex revision cases. Accurate coding of comorbidities and procedure details determines classification into this Diagnosis-Related Group and affects Medicare inpatient reimbursement.
Clinical Trials
- Perioperative infection prevention and management studies focusing on reduced postoperative complications after revision hip or knee arthroplasty: randomized or pragmatic trials compare different perioperative antibiotic strategies, surgical debridement protocols, or intraoperative antiseptic techniques in patients undergoing revision for suspected or confirmed prosthetic joint infection. These studies enroll older adults with prior joint arthroplasty, often with comorbidities (diabetes, obesity, immunosuppression) that increase infection risk, and aim to define interventions that lower reoperation rates and length of stay. Results directly inform hospital protocols and payer quality metrics by targeting readmissions, costly re-revisions, and resource utilization in this high-cost DRG population.
- Comparative effectiveness trials evaluating implant and fixation strategies for aseptic mechanical failure in revision arthroplasty: observational cohorts or randomized studies examining different revision implants (modular stems, constrained liners, megaprotheses), fixation methods (cemented vs. cementless), and bone defect management techniques in patients revised for loosening, instability, or periprosthetic fracture. These trials typically involve older patients with variable bone loss and functional demands, and they measure durable outcomes such as implant survival, functional scores, and perioperative complications over 1–5 years. Findings help surgeons and payers decide which devices and approaches offer the best balance of long-term outcomes and upfront costs for patients classified under this DRG.
- Post-discharge outcomes and care pathway research assessing rehabilitation, readmission prevention, and cost-effectiveness after revision hip/knee surgery: prospective cohort studies and pragmatic trials test differing rehabilitation intensities, bundled care pathways, remote monitoring, and transitional care interventions in the early post-discharge period to reduce complications, prosthesis-related problems, and unplanned readmissions. The studied population includes frail, multimorbid patients discharged from acute care after complex revisions who are at high risk for complications and extended recovery; endpoints include functional recovery, quality of life, readmission rates, and total episode-of-care costs. This area is critical for payers and hospitals aiming to optimize reimbursements and outcomes under value-based payment models for DRG 468 admissions.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.